143426-39-5

Basic information

• Product Name: 2-(4-[METHYLSULFONYL]PHENYL)-1H-BENZIMIDAZOLE
• Synonyms: 2-(4-[METHYLSULFONYL]PHENYL)-1H-BENZIMIDAZOLE;IS-22
• CAS NO: 143426-39-5
• Molecular Formula: C₁₄H₁₂N₂O₂S
• Molecular Weight: 0
• Mol File: 143426-39-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-[METHYLSULFONYL]PHENYL)-1H-BENZIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-[METHYLSULFONYL]PHENYL)-1H-BENZIMIDAZOLE(143426-39-5)
• EPA Substance Registry System: 2-(4-[METHYLSULFONYL]PHENYL)-1H-BENZIMIDAZOLE(143426-39-5)

Safety Data

• Hazardous Substances Data: 143426-39-5(Hazardous Substances Data)

Usage

Chemical Class

Benzimidazole

Type of Compound

Heterocyclic compound

Structure

Contains a benzene ring fused to an imidazole ring

Derivative

2-(4-[methylsulfonyl]phenyl)-1H-benzimidazole is a derivative of benzimidazole with a methylsulfonyl group attached to the 4-position of the phenyl ring.

Biological and Pharmacological Activities

It has been studied for its potential as an anti-cancer agent.

Research and Development Value

Its structure and properties make it a valuable chemical for research and potential drug development.

Upstream product

• 57870-36-7 4-methanesulfonyl-benzimidic acid ethyl ester 
• 95-54-5 1,2-diamino-benzene 
• 5398-77-6 para-methanesulfonylbenzaldehyde 
• 3446-89-7 4-(Methylthio)benzaldehyde 
• 104-96-1 4-methylsulfanylaniline 
• 22821-76-7 4-(methylsulfonyl)benzonitrile 
• 21382-98-9 p-cyanophenyl methyl sulfide 
• 4052-30-6 4-methylsulfonylbenzoic acid 
• 725701-22-4 2-(4-(methylthio)phenyl)-1H-benzo[d]imidazole 

Relevant articles and documents

Design, synthesis, biological assessment and: In silico ADME prediction of new 2-(4-(methylsulfonyl) phenyl) benzimidazoles as selective cyclooxygenase-2 inhibitors

A novel series of benzimidazole derivatives wherein 4-(methylsulfonyl) phenyl pharmacophore attached via its C-2 position was designed and synthesized. These compounds were evaluated in vitro as cyclooxygenase-1(COX-1)/cyclooxygenese-2(COX-2) inhibitors. Furthermore, the synthesized compounds were also in vivo evaluated for their anti-inflammatory activity and ulcerogenic liability. Examination of histopathological lesions was also performed to evaluate the cariogenic effect of most active compounds. In silico prediction of physicochemical properties, ADME, and drug-likeness profiles were also studied. Several compounds as 11b, 11k, 12b, and 12d showed selective inhibition to (COX-2) isozyme. Compound 11b showed the most potent (COX-2) inhibitory activity with (IC50 = 0.10 μM) and selectivity index (SI = 134); the tested compounds also have shown good anti-inflammatory activity. Regarding the ulcerogenic liability, compound 11b was also safest one (Ulcer Index) (UI = 0.83). The results of the molecular docking studies is closely related to the results of the in vitro COX-2 inhibitory activities.

Conventional and microwave-assisted synthesis of benzimidazole derivatives and their in vitro inhibition of human cyclooxygenase

A large series of 1,2-diaryl-benzimidazole and 2-aryl-1H-benzimidazole derivatives were synthesized with slight differences using both microwave irradiation and conventional heating methods. Usually higher yields and time reactions reduction were obtained

2-Aryl-substituted benzo-anellated 5-membered heterocycles as potential effectors in the cardiovascular system. Part 2

In the course of investigations on structure-activity relationships of fostedil-and sulmazole-analoguesly fused 5-membered heterocycles, 1,3-benzimidazoles were obtained by simple cyclisation. In vitro experiments on isolated organs demonstrate markedly positive inotropic effects of some derivatives, whereas others exert both relaxing activity on smooth musculature in vitro and antihypertensive effects in vivo. Moreover they exhibit fungicide properties in vitro.